EXTRAMEDULLARY MYELOMA: CHALLENGES
AND CAR-T CONSIDERATIONS

Multiple myeloma is a cancer of plasma cells that traditionally lives in the bone marrow. In a subset of patients, the disease finds ways to grow outside the marrow environment. When this happens, behaviour, response to treatment, and prognosis all shift. The term “extramedullary myeloma” covers a few different patterns, and distinguishing between them matters because the implications are not identical. Extramedullary disease can appear at the time of initial diagnosis or develop later in the course of the disease, often at relapse. Late-onset extramedullary disease, sometimes seen after multiple lines of therapy and after stem cell transplant, tends to behave more aggressively than extramedullary disease present from the outset.

Several biological and clinical features come together to make extramedullary disease harder to treat than marrow-confined myeloma: These features are why families with extramedullary myeloma often hear language like “we need to act quickly” and “we should consider more intensive therapy.” That clinical urgency is real, and it changes how decisions about CAR T-cell therapy and other cellular treatments are made.

• Adverse cytogenetics. Extramedullary disease is enriched for

  Adverse cytogenetics. Extramedullary disease is enriched for high-risk features such as del(17p) and TP53 mutations, MYC abnormalities, and 1q gain or amplification, which are themselves associated with shorter remissions.

• Different microenvironment. Outside the bone marrow, the pro

  Different microenvironment. Outside the bone marrow, the protective and supportive cell signals that some standard agents rely on for activity differ. Drugs that work well in marrow disease may not work as well in soft tissue lesions.

• Faster disease tempo. Extramedullary lesions can grow rapidl

  Faster disease tempo. Extramedullary lesions can grow rapidly, sometimes within weeks, which compresses the time available for planning and treatment delivery.

• Shorter responses. Even when extramedullary disease responds

  Shorter responses. Even when extramedullary disease responds to systemic therapy, the responses tend to be shallower and shorter than in marrow disease.

• Anatomic challenges. Some sites, particularly central nervou

  Anatomic challenges. Some sites, particularly central nervous system involvement, present additional anatomic and pharmacological barriers to therapy.

• Imaging complexity. Standard skeletal surveys can miss true

  Imaging complexity. Standard skeletal surveys can miss true extramedullary disease. PET CT and whole-body MRI are usually needed to map the disease properly.

BCMA CAR T-cell therapy has been transformative for many relapsed and refractory myeloma patients, including a large number treated in Chinese centres. Response rates are high in marrow-confined disease and remissions can be deep and durable. The picture in extramedullary disease is more nuanced. Across reported series, including data from major Chinese and international centres, response rates tend to be numerically lower in patients with extramedullary disease, and the duration of response is typically shorter. CAR T-cell therapy is still often the best available option for these patients, but expectations need to be set honestly. Several factors contribute to the different behaviour of CAR-T in extramedullary disease: These factors do not mean CAR T-cell therapy is the wrong choice in extramedullary myeloma. They mean the planning has to be more careful: realistic bridging strategy, proper imaging at baseline and after infusion, and contingency planning for the possibility that response is shorter than in marrow-confined disease. Emerging directions: GPRC5D, FcRH5, and dual-target CAR-T Because BCMA-only CAR-T may have limitations in extramedullary disease, there is significant interest in alternative or combined targets. Several Chinese centres run trials of CAR T-cell therapy targeting GPRC5D, FcRH5, and dual antigens such as BCMA-CD19 or BCMA-GPRC5D. The intent is to broaden the surface targets the engineered T cells can recognise, reducing the chance of antigen escape and potentially improving activity in soft-tissue and organ-based lesions. These options are still investigational and access is through clinical trials with their own eligibility rules. For some heavily pre-treated patients with extramedullary disease, however, they expand the realistic next-step list in ways that are not always available outside specialised centres.

Treatment for extramedullary myeloma is typically multi-modal. The aim is to bring the disease under control quickly, achieve a meaningful response, and where possible consolidate that response with cellular therapy. Chinese centres typically combine: What fits an individual patient depends on disease tempo, prior therapy, performance status, organ function, available targets on the tumour, and whether there is a feasible bridging strategy to keep the disease under control during CAR-T manufacturing.

There is no single profile of an EMM patient who fits a single treatment plan. Suitability for each option is assessed against: Patients with very rapidly progressing disease may need stabilisation with intensive systemic therapy or local radiation before international travel for cellular therapy can be considered safely.

• Confirmed myeloma diagnosis with FISH cytogenetics, ISS or R

  Confirmed myeloma diagnosis with FISH cytogenetics, ISS or R-ISS staging, and full disease mapping with PET CT or whole-body MRI

• Pattern of extramedullary disease (paraskeletal, distant sof

  Pattern of extramedullary disease (paraskeletal, distant soft tissue or organ, or plasma cell leukemia)

• Sites of involvement and any compressive or organ-threatenin

  Sites of involvement and any compressive or organ-threatening lesions that need urgent local control

• Disease tempo at the time of decision (slowly evolving versu

  Disease tempo at the time of decision (slowly evolving versus rapidly progressing)

• Cumulative prior therapy and response, including drug classe

  Cumulative prior therapy and response, including drug classes already used

• BCMA expression where available, and consideration of altern

  BCMA expression where available, and consideration of alternative targets such as GPRC5D

• Cardiac, pulmonary, hepatic, and renal function

  Cardiac, pulmonary, hepatic, and renal function

• Performance status and frailty assessment

  Performance status and frailty assessment

• Adequate T-cell counts for CAR T-cell manufacturing, or adeq

  Adequate T-cell counts for CAR T-cell manufacturing, or adequate stem cell collection for transplant

• Feasibility of an effective bridging strategy during CAR-T m

  Feasibility of an effective bridging strategy during CAR-T manufacturing

• Travel fitness and ability to remain in China for the planne

  Travel fitness and ability to remain in China for the planned duration

A meaningful EMM assessment depends on careful disease mapping and complete prior therapy records. The records most centres in China will want to see include: If reports are in a regional language, English translations help the review move faster. Where reports are missing, our team helps the family identify what to request from the treating hospital before submission.

• Latest medical summary and diagnosis report

  Latest medical summary and diagnosis report

• Bone marrow aspirate and biopsy reports, including plasma ce

  Bone marrow aspirate and biopsy reports, including plasma cell percentage and immunophenotyping (flow cytometry)

• FISH cytogenetics and karyotype reports, with attention to d

  FISH cytogenetics and karyotype reports, with attention to del(17p), t(4;14), t(14;16), t(14;20), 1q gain or amplification, and del(1p)

• Histopathology and immunohistochemistry from any biopsied ex

  Histopathology and immunohistochemistry from any biopsied extramedullary lesion, including BCMA staining where available

• PET CT and whole-body MRI reports — critical for mapping ext

  PET CT and whole-body MRI reports — critical for mapping extramedullary disease

• Any CT, MRI, or ultrasound reports of involved sites (CNS, a

  Any CT, MRI, or ultrasound reports of involved sites (CNS, abdomen, chest, skin)

• Serum protein electrophoresis (SPEP), serum immunofixation,

  Serum protein electrophoresis (SPEP), serum immunofixation, serum free light chains, and 24-hour urine studies

• Quantitative immunoglobulins, beta-2 microglobulin, albumin,

  Quantitative immunoglobulins, beta-2 microglobulin, albumin, LDH, calcium, creatinine, and full blood counts

• Peripheral blood smear and flow cytometry if plasma cell leu

  Peripheral blood smear and flow cytometry if plasma cell leukemia is suspected

• Echocardiogram and pulmonary function tests where available

  Echocardiogram and pulmonary function tests where available

• Infection screening

  hepatitis B, hepatitis C, HIV, syphilis, CMV, and tuberculosis status

• Full record of all prior therapy with regimen, doses, dates,

  Full record of all prior therapy with regimen, doses, dates, cycles, best response, and reason for switch

CancerFax supports families with extramedullary myeloma through a structured pathway:

• Case review and disease mapping check. We review the diagnos

  Case review and disease mapping check. We review the diagnosis, cytogenetics, imaging, and prior therapy to confirm the pattern of extramedullary disease and identify what additional investigations may be needed before review (most often PET CT or whole-body MRI if not already done).

• Centre and trial matching. Records are shared with appropria

  Centre and trial matching. Records are shared with appropriate hematology and CAR T-cell therapy teams in China. Where commercial BCMA CAR-T is the right fit, we connect to centres with EMM experience. Where trial-based options (GPRC5D, FcRH5, or dual-target constructs) may add value, we identify those pathways.

• Bridging strategy planning. For CAR-T pathways, we help the

  Bridging strategy planning. For CAR-T pathways, we help the family understand what bridging therapy may be used during the manufacturing window and why this is particularly important in EMM.

• Treatment planning and cost clarity. Once a centre accepts t

  Treatment planning and cost clarity. Once a centre accepts the case for management, the family receives a planning package covering the proposed sequence, expected stay, and a realistic cost range with assumptions clearly listed.

• Visa, travel, and admission coordination. Medical visa invit

  Visa, travel, and admission coordination. Medical visa invitation, accommodation suitable for an immunocompromised patient, interpreter support, and admission window are aligned so that arrival is smooth and the patient is not exposed to unnecessary delays.

• On-ground support during treatment. From admission through d

  On-ground support during treatment. From admission through discharge, we stay involved as a single point of contact for the family, translating medical updates, supporting communication when the plan changes, and helping the family understand what is happening during CAR-T or transplant recovery.

• Discharge and home-country follow-up. Before the family leav

  Discharge and home-country follow-up. Before the family leaves, we help compile the treatment summary, CAR T product or conditioning details, recovery course, and recommended monitoring plan in a clean format the local hematologist can use to continue care.

Several major centres in China have substantial experience with high-risk and extramedullary myeloma, often paired with active CAR T-cell therapy and trial portfolios. Examples that families commonly ask about include: The most appropriate centre depends on the pattern of extramedullary disease, prior treatment, urgency, and the family's practical situation. CancerFax helps families select a centre that fits the case rather than choosing by name alone, and prioritises centres with documented experience managing extramedullary presentations.

• Institute of Hematology and Blood Diseases Hospital, Chinese

  Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin) — a leading national hematology centre with deep myeloma experience

• Changzheng Hospital, Shanghai — significant CAR T-cell thera

  Changzheng Hospital, Shanghai — significant CAR T-cell therapy volume in myeloma

• Ruijin Hospital, Shanghai — long-standing leukaemia and myel

  Ruijin Hospital, Shanghai — long-standing leukaemia and myeloma programmes with active research

• Peking University People's Hospital, Beijing — well-known fo

  Peking University People's Hospital, Beijing — well-known for hematology, transplant, and cellular therapy

• First Affiliated Hospital of Soochow University (Suzhou) — s

  First Affiliated Hospital of Soochow University (Suzhou) — strong transplant and cell therapy services

• First Affiliated Hospital of Zhejiang University, Hangzhou —

  First Affiliated Hospital of Zhejiang University, Hangzhou — active hematology and trial portfolio

• Shanghai GoBroad Cancer Institute and Royal Lee Cancer Hospi

  Shanghai GoBroad Cancer Institute and Royal Lee Cancer Hospital network — experienced in transplant and BCMA CAR T-cell therapy

• Other university and provincial cancer hospitals with cell t

  Other university and provincial cancer hospitals with cell therapy accreditation and active trial enrolment

Frequently Asked Questions

Answers to common questions from patients and families.

Structured reference data summarizing key information for this topic.

Structured reference data summarizing key information for this topic.

Structured reference data summarizing key information for this topic.